179 related articles for article (PubMed ID: 36684904)
1. Impact of human papillomavirus vaccine on cervical cancer epidemic: Evidence from the surveillance, epidemiology, and end results program.
Pei J; Shu T; Wu C; Li M; Xu M; Jiang M; Zhu C
Front Public Health; 2022; 10():998174. PubMed ID: 36684904
[TBL] [Abstract][Full Text] [Related]
2. Investigating the Efficacy of HPV Vaccines in Preventing Cervical Cancer from 2006 to 2018 in the US: A SEER Data Set Analysis.
Mattis A; Beydoun H; Dobrydneva Y; Ganjoo R
Rev Recent Clin Trials; 2023; 18(3):214-222. PubMed ID: 37046192
[TBL] [Abstract][Full Text] [Related]
3. Update of HPV-associated female genital cancers in the United States, 1999-2004.
Watson M; Saraiya M; Wu X
J Womens Health (Larchmt); 2009 Nov; 18(11):1731-8. PubMed ID: 19951205
[TBL] [Abstract][Full Text] [Related]
4. Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction.
Guo F; Cofie LE; Berenson AB
Am J Prev Med; 2018 Aug; 55(2):197-204. PubMed ID: 29859731
[TBL] [Abstract][Full Text] [Related]
5. Trends and future projections of cervical cancer-related outcomes in Japan: What happens if the HPV vaccine program is not implemented?
Sakakibara A; Nakayama T; Uchida H; Odagiri Y; Ito Y; Katayama T; Ueda Y; Higuchi T; Terakawa K; Matsui K; Miyazaki K; Konishi I
Int J Cancer; 2023 May; 152(9):1863-1874. PubMed ID: 36468173
[TBL] [Abstract][Full Text] [Related]
6. Assessing Impact of HPV Vaccination on Cervical Cancer Incidence among Women Aged 15-29 Years in the United States, 1999-2017: An Ecologic Study.
Mix JM; Van Dyne EA; Saraiya M; Hallowell BD; Thomas CC
Cancer Epidemiol Biomarkers Prev; 2021 Jan; 30(1):30-37. PubMed ID: 33082207
[TBL] [Abstract][Full Text] [Related]
7. Trends in Human Papillomavirus-Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017.
Liao CI; Francoeur AA; Kapp DS; Caesar MAP; Huh WK; Chan JK
JAMA Netw Open; 2022 Mar; 5(3):e222530. PubMed ID: 35294540
[TBL] [Abstract][Full Text] [Related]
8. MOnitoring human papillomavirus Vaccine effect on Infection and cErvical diseases (MOVIE): Protocol for a cohort study using electronic health records from Yinzhou, China.
Deng S; Welby S; Liu Z; Yang Y; Meng R; Sun Y; Yang J; Liu G; He Y; Jiang N; Wu Z; Liu K; Rosillon D; Cohet C; Borys D; Zhan S
Hum Vaccin Immunother; 2023 Aug; 19(2):2257989. PubMed ID: 37813849
[TBL] [Abstract][Full Text] [Related]
9. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
10. Cancers attributable to human papillomavirus infection.
Grulich AE; Jin F; Conway EL; Stein AN; Hocking J
Sex Health; 2010 Sep; 7(3):244-52. PubMed ID: 20719211
[TBL] [Abstract][Full Text] [Related]
11. Incidence of cervical precancerous lesions and cervical cancer in Denmark from 2000 to 2019: Population impact of multi-cohort vaccination against human papillomavirus infection.
Ring LL; Munk C; Galanakis M; Tota JE; Thomsen LT; Kjaer SK
Int J Cancer; 2023 Apr; 152(7):1320-1327. PubMed ID: 36250312
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
13. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
[TBL] [Abstract][Full Text] [Related]
14. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
15. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.
Jemal A; Simard EP; Dorell C; Noone AM; Markowitz LE; Kohler B; Eheman C; Saraiya M; Bandi P; Saslow D; Cronin KA; Watson M; Schiffman M; Henley SJ; Schymura MJ; Anderson RN; Yankey D; Edwards BK
J Natl Cancer Inst; 2013 Feb; 105(3):175-201. PubMed ID: 23297039
[TBL] [Abstract][Full Text] [Related]
16. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus vaccine impact on invasive cervical cancer in Japan: Preliminary results from cancer statistics and the MINT study.
Onuki M; Takahashi F; Iwata T; Nakazawa H; Yahata H; Kanao H; Horie K; Konnai K; Nio A; Takehara K; Kamiura S; Tsuda N; Takei Y; Shigeta S; Matsumura N; Yoshida H; Motohara T; Yamazaki H; Nakamura K; Hamanishi J; Tasaka N; Ishikawa M; Hirashima Y; Kudaka W; Mori-Uchino M; Kukimoto I; Fujii T; Watanabe Y; Noda K; Yoshikawa H; Yaegashi N; Matsumoto K;
Cancer Sci; 2023 Nov; 114(11):4426-4432. PubMed ID: 37688310
[TBL] [Abstract][Full Text] [Related]
19. Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination.
Pimenta JM; Galindo C; Jenkins D; Taylor SM
BMC Cancer; 2013 Nov; 13():553. PubMed ID: 24261839
[TBL] [Abstract][Full Text] [Related]
20. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
